Prescription omega-3-acid ethyl esters reduce fasting and postprandial triglycerides and modestly reduce pancreatic Β-cell response in subjects with primary hypertriglyceridemia

Prostaglandins Leukotrienes and Essential Fatty Acids

Volumn 85, Issue 3-4, 2011, Pages 143-148

  Maki, Kevin C ^a   Lawless, Andrea L ^a   Kelley, Kathleen M ^a   Dicklin, Mary R ^a   Schild, Arianne L ^a   Rains, Tia M ^a  

^a Provident Clinical Research/Biofortis North America   (United States)

Author keywords

Dyslipidemia; Glucose; Insulin sensitivity; Omega 3 fatty acids; Triglyceride

Indexed keywords

CORN OIL; GLUCOSE; OMEGA 3 FATTY ACID ESTER; PLACEBO;

ADULT; ARTICLE; BODY WEIGHT; BRONCHITIS; CELL FUNCTION; CLINICAL ARTICLE; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG RESPONSE; FEMALE; GLUCOSE HOMEOSTASIS; HUMAN; HYPERTRIGLYCERIDEMIA; INSULIN RELEASE; INSULIN SENSITIVITY; LIPID COMPOSITION; LYMPHOCYTE COUNT; MALE; PANCREAS ISLET BETA CELL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; TREATMENT OUTCOME;

BLOOD GLUCOSE; CROSS-OVER STUDIES; DOCOSAHEXAENOIC ACIDS; DOUBLE-BLIND METHOD; EICOSAPENTAENOIC ACID; FASTING; FEMALE; HUMANS; HYPERTRIGLYCERIDEMIA; INSULIN RESISTANCE; INSULIN-SECRETING CELLS; LIPIDS; MALE; MIDDLE AGED; POSTPRANDIAL PERIOD; PRESCRIPTION DRUGS; TRIGLYCERIDES;

ZEA MAYS;

EID: 80052273587     PISSN: 09523278     EISSN: 15322823     Source Type: Journal    
DOI: 10.1016/j.plefa.2011.06.005     Document Type: Article

References (37)

1. Davidson M.H., Stein E.A., Bays H.E., et al. Efficacy and tolerability of adding prescription omega-3 fatty acids 4g/d to simvastatin 40mg/d in hypertriglyceridemic patients: an 8-week, randomized, double-blind, placebo-controlled study. Clin. Ther. 2007, 29:1354-1367.
2. Davidson M.H., Maki K.C., Bays H., Carter R., Ballantyne C.M. Effects of prescription omega-3-acid ethyl esters on lipoprotein particle concentrations, apolipoproteins AI and CIII, and lipoprotein-associated phospholipase A(2) mass in statin-treated subjects with hypertriglyceridemia. J. Clin. Lipidol. 2009, 3:332-340.
3. Maki K.C., McKenney J.M., Reeves M.S., Lubin B.C., Dicklin M.R. Effects of adding prescription omega-3 acid ethyl esters to simvastatin (20mg/day) on lipids and lipoprotein particles in men and women with mixed dyslipidemia. Am. J. Cardiol. 2008, 102:429-433.
4. Adeli K., Taghibiglou C., Van Iderstine S.C., Lewis G.F. Mechanisms of hepatic very low-density lipoprotein overproduction in insulin resistance. Trends Cardiovasc. Med. 2001, 11:170-176.
5. Maki K.C. Fibrates for treatment of the metabolic syndrome. Curr. Atheroscler. Rep. 2004, 6:45-51.
6. Ginsberg H.N., Zhang Y.L., Hernandez-Ono A. Regulation of plasma triglycerides in insulin resistance and diabetes. Arch. Med. Res. 2005, 36:232-240.
7. DeFronzo R.A. Lilly lecture 1987. The triumvirate: beta-cell, muscle, liver: a collusion responsible for NIDDM. Diabetes 1988, 37:667-687.
8. DeFronzo R.A., Tripathy D. Skeletal muscle insulin resistance is the primary defect in type 2 diabetes. Diabetes Care 2009, 32(Suppl. 2):S157-S163.
9. Friedberg C.E., Janssen M.J., Heine R.J., Grobbee D.E. Fish oil and glycemic control in diabetes. A meta-analysis. Diabetes Care 1998, 21:494-500.
10. Montori V.M., Farmer A., Wollan P.C., Dinneen S.F. Fish oil supplementation in type 2 diabetes: a quantitative systematic review. Diabetes Care 2000, 23:1407-1415.
11. Woodman R.J., Mori T.A., Burke V., Puddey I.B., Watts G.F., Beilin L.J. Effects of purified eicosapentaenoic and docosahexaenoic acids on glycemic control, blood pressure, and serum lipids in type 2 diabetic patients with treated hypertension. Am. J. Clin. Nutr. 2002, 76:1007-1015.
12. Agency for Healthcare Research and Quality. AHRQ Publication No. 04-E012-2, Effects of Omega-3 Fatty Acids on Lipids and Glycemic Control in Type II Diabetes and the Metabolic Syndrome and on Inflammatory Bowel Disease, Rheumatoid Arthritis, Renal Disease, Systemic Lupus Erythematosus, and Osteoporosis, March 2004.
13. Mori T.A., Burke V., Puddey I.B., et al. Purified eicosapentaenoic and docosahexaenoic acids have differential effects on serum lipids and lipoproteins, LDL particle size, glucose, and insulin in mildly hyperlipidemic men. Am. J. Clin. Nutr. 2000, 71:1085-1094.
14. Kelley D.S., Siegel D., Vemuri M., Mackey B.E. Docosahexaenoic acid supplementation improves fasting and postprandial lipid profiles in hypertriglyceridemic men. Am. J. Clin. Nutr. 2007, 86:324-333.
15. Frayn K.N. Non-esterified fatty acid metabolism and postprandial lipaemia. Atherosclerosis 1998, 141(Suppl. 1):S41-S46.
16. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults: third report of the national cholesterol education program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III) final report. Circulation 106 (2002) 3143-3421.
17. Matsuda M., DeFronzo R.A. Insulin sensitivity indices obtained from oral glucose tolerance testing: comparison with the euglycemic insulin clamp. Diabetes Care 1999, 22:1462-1470.
18. Maki K.C., McKenney J.M., Farmer M.V., Reeves M.S., Dicklin M.R. Indices of insulin sensitivity and secretion from a standard liquid meal test in subjects with type 2 diabetes, impaired or normal fasting glucose. Nutr. J. 2009, 8:22.
19. Maki K.C., Rains T.M., Dicklin M.R., Bell M. Repeatability of indices of insulin sensitivity and secretion from standard liquid meal tests in subjects with type 2 diabetes mellitus or normal or impaired fasting glucose. Diabetes Technol. Ther. 2010, 12:895-900.
20. Maki K.C., Kelley K.M., Lawless A.L., et al. Validation of insulin sensitivity and secretion indices derived from the liquid meal tolerance test. Diabetes Technol. Ther. 2011, 13:661-666.
21. Retnakaran R., Shen S., Hanley A.J., Vuksan V., Hamilton J.K., Zinman B. Hyperbolic relationship between insulin secretion and sensitivity on oral glucose tolerance test. Obesity (Silver Spring) 2008, 16:1901-1907.
22. Friedewald W.T., Levy R.I., Fredrickson D.S. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin. Chem. 1972, 18:499-502.
23. Holness M.J., Smith N.D., Greenwood G.K., Sugden M.C. Acute omega-3 fatty acid enrichment selectively reverses high-saturated fat feeding-induced insulin hypersecretion but does not improve peripheral insulin resistance. Diabetes 2004, 53(Suppl. 1):S166-S171.
24. Holness M.J., Greenwood G.K., Smith N.D., Sugden M.C. Diabetogenic impact of long-chain omega-3 fatty acids on pancreatic beta-cell function and the regulation of endogenous glucose production. Endocrinology 2003, 144:3958-3968.
25. Giacco C., Cuomo V., Vessby B., et al. Fish oil, insulin sensitivity, insulin secretion and glucose tolerance in healthy people: is there any effect of fish oil supplementation in relation to the type of background diet and habitual dietary intake of n-6 and n-3 fatty acids?. Nutr. Metab. Cardiovasc. Dis. 2007, 17:572-580.
26. Maki K.C., Lubin B.C., Reeves M.S., Dicklin M.R., Harris W.S. Prescription omega-3 acid ethyl esters plus simvastatin 20 and 80mg: effects in mixed dyslipidemia. J. Clin. Lipidol. 2009, 3:33-38.
27. Maki K.C., Lawless A.L., Kelley K.M., et al. Effects of prescription omega-3-acid ethyl esters on fasting lipid profile in subjects with primary hypercholesterolemia. J. Cardiovasc. Pharmacol. 2011, 57:489-494.
28. Borkman M., Chisholm D.J., Furler S.M., et al. Effects of fish oil supplementation on glucose and lipid metabolism in NIDDM. Diabetes 1989, 38:1314-1319.
29. Rivellese A.A., Maffettone A., Iovine C., et al. Long-term effects of fish oil on insulin resistance and plasma lipoproteins in NIDDM patients with hypertriglyceridemia. Diabetes Care 1996, 19:1207-1213.
30. Kabir M., Skurnik G., Naour N., et al. Treatment for 2 mo with n 3 polyunsaturated fatty acids reduces adiposity and some atherogenic factors but does not improve insulin sensitivity in women with type 2 diabetes: a randomized controlled study. Am. J. Clin. Nutr. 2007, 86:1670-1679.
31. Mostad I.L., Bjerve K.S., Bjorgaas M.R., Lydersen S., Grill V. Effects of n-3 fatty acids in subjects with type 2 diabetes: reduction of insulin sensitivity and time-dependent alteration from carbohydrate to fat oxidation. Am. J. Clin. Nutr. 2006, 84:540-550.
32. Harris W.S. Fish oils and plasma lipid and lipoprotein metabolism in humans: a critical review. J. Lipid Res. 1989, 30:785-807.
33. Harris W.S. n-3 fatty acids and serum lipoproteins: human studies. Am. J. Clin. Nutr. 1997, 65(Suppl. 5):1645S-1654S.
34. Harris W.S., Miller M., Tighe A.P., Davidson M.H., Schaefer E.J. Omega-3 fatty acids and coronary heart disease risk: clinical and mechanistic perspectives. Atherosclerosis 2008, 197:12-24.
35. Lovaza® (omega-3-acid ethyl esters) Capsules. Prescribing information. GlaxoSmithKline, Research Triangle Park, NC, December 2010.
36. Maki K.C., Dicklin M.R., Lawless A., Reeves M.S. Omega-3 fatty acids for the treatment of elevated triglycerides. Clin. Lipidol. 2009, 4:425-437.
37. Stern M.P., Williams K., Haffner S.M. Identification of persons at high risk for type 2 diabetes mellitus. Do we need the oral glucose tolerance test? Ann. Intern. Med. 2002, 136:575-581.